Swissmedic Role and Limits: What It Does and Does Not Do

This article is number 03 in Volume 1, Regulatory Framework and Fundamentals, of the fifty-part series on medical device registration in Switzerland. Together with the other nine articles in this volume it forms a complete deliverable on this topic. The publication timestamp, article number, article title and unique URL are listed in the table below.

1. Key takeaways

Swissmedic is an enforcement and supervisory authority, not a consultancy. It is empowered to conduct official market surveillance, to verify and allocate the Swiss single registration number (CHRN), and to receive notifications and vigilance reports. It expressly does not provide advice on the development, characterisation, classification, registration or placing on the market of medical devices; such judgments rest entirely with the company, which must commission private consultants at its own initiative. Planning a Swiss project means building the schedule around what the authority will do on fixed timelines and fees, and arranging private support for everything the authority deliberately leaves to the operator.

2. Legal basis

Verification entry points: the official Swissmedic statement that no advice is given on device development, characterisation, classification, registration or placing on the market; and its FAQ Notifications (BW630_30_009e_MB, PDF, 01.07.2026). These documents define the boundary between the authority’s administrative services and the responsibilities that remain with the operator, and they should be cited whenever an internal expectation about Swissmedic support needs to be corrected.

3. Expert insights

1. What it is empowered to do: administrative tasks with fixed timelines and fees. Official market surveillance (TPA Art. 58), verification and allocation of the CHRN (MedDO Art. 55(4), processing applications in up to 30 days), and receipt of serious incident and field safety corrective action reports (Art. 66). These are predictable, priceable and schedulable steps; companies should build project plans backwards from these deadlines, because they are the only milestones the authority itself commits to, and missing them carries procedural consequences rather than discretionary tolerance. Treat these three functions as the fixed backbone of the project calendar and hang all private workstreams around them.
2. What it expressly does not do: characterisation, classification and registration advice. Conclusion: characterisation is precisely the highest-risk step in the whole compliance chain, and Switzerland leaves it entirely to the operator, which means the cost of an error stays with the company and cannot be recovered from the authority. The counterpoint: some companies hope to obtain written confirmation through queries in order to lock down risk; this route does not exist. The workable alternative is to commission private consultants for a written opinion and retain it, so that it can serve as evidence of due diligence in any later dispute.
3. System boundary: swissdamed and EUDAMED have no interface and cannot synchronise. Conclusion: this is a direct consequence of Switzerland being a third country to the EU at the information-system level, and any workflow designed around a single upload taking effect in both systems must be redesigned. The pragmatic workaround is to document the field differences between the two datasets as a checklist and upload the same master data twice, rather than waiting for a synchronisation capability that is not on any published roadmap. Budgeting for the dual submission should include the staff time for keeping both datasets aligned after every change, since a discrepancy between the two registers is itself a finding an inspector can raise.

4. Practical recommendations

1. Fix characterisation and classification conclusions in written internal decision documents, citing the instrument name, provision number and version date, and do not rely on oral confirmations.
2. Schedule CHRN applications against the maximum 30-day processing period; where an objection requires rectification, the response must be submitted within 30 days, after which the application is rejected.
3. The CHRN fixed fee under Annex II is CHF 200; a rejected application is charged by actual working hours (Art. 4(2)), so rejection risk belongs in the budget.
4. Establish a dual upload mechanism for swissdamed and EUDAMED and maintain a fixed field-difference checklist between the two datasets.
5. Record the scope, form and archiving of private consultant engagements in the quality management system documents, as one link in the chain of due diligence evidence.

5. Verification checklist

• □ Characterisation and classification conclusions exist as written documents stating the regulatory version
• □ CHRN applications are scheduled against the 30-day processing cap
• □ The 30-day deadline for responding to objections is in the calendar with reminders
• □ It is confirmed that swissdamed and EUDAMED require separate uploads with no automatic synchronisation
• □ Private consultant opinions are archived and usable as evidence of due diligence
• □ Vigilance reporting owners and electronic submission channels are designated internally

Regulatory information verified as of 29 October 2026.

GRZAN supports manufacturers and economic operators entering the Swiss market with end-to-end Swissmedic registration and compliance services, including CHRN applications and objection management, swissdamed and EUDAMED dual upload strategies, characterisation and classification opinions retained as due diligence evidence, and vigilance process setup. Our team fills precisely the gap Swissmedic deliberately leaves to operators. For tailored guidance on your product portfolio, contact info@grzanglobal.com.